Effectiveness of messenger RNA vaccines against infection with SARS-CoV-2 during the periods of Delta and Omicron variant predominance in Japan: the Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study

OBJECTIVES: We aimed to evaluate COVID-19 messenger RNA vaccine effectiveness during the Delta- and Omicron-predominant periods in Japan. METHODS: We conducted a population-based cohort study among individuals aged 16–64 years during two periods: the Delta-predominant period (July 1–December 31, 202...

Descripción completa

Detalles Bibliográficos
Autores principales: Mimura, Wataru, Ishiguro, Chieko, Maeda, Megumi, Murata, Fumiko, Fukuda, Haruhisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2022
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547653/
https://www.ncbi.nlm.nih.gov/pubmed/36220547
http://dx.doi.org/10.1016/j.ijid.2022.10.001
_version_ 1784805311134040064
author Mimura, Wataru
Ishiguro, Chieko
Maeda, Megumi
Murata, Fumiko
Fukuda, Haruhisa
author_facet Mimura, Wataru
Ishiguro, Chieko
Maeda, Megumi
Murata, Fumiko
Fukuda, Haruhisa
author_sort Mimura, Wataru
collection PubMed
description OBJECTIVES: We aimed to evaluate COVID-19 messenger RNA vaccine effectiveness during the Delta- and Omicron-predominant periods in Japan. METHODS: We conducted a population-based cohort study among individuals aged 16–64 years during two periods: the Delta-predominant period (July 1–December 31, 2021) and the Omicron-predominant period (January 1–March 29, 2022). RESULTS: When comparing individuals who were vaccinated with those who were unvaccinated, the effectiveness of a second dose against symptomatic infection was 89.8% (95% confidence interval [CI]: 80.5–94.7%) during the Delta-predominant period and 21.2% (95% CI: 11.0–30.3%) during the Omicron-predominant period. The effectiveness of a third dose against symptomatic infection was 71.8% (95% CI: 60.1–80.1%) during the Omicron-predominant period. CONCLUSION: Vaccine effectiveness against symptomatic infection decreased during the Omicron-predominant period but was maintained by a third dose.
format Online
Article
Text
id pubmed-9547653
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
record_format MEDLINE/PubMed
spelling pubmed-95476532022-10-11 Effectiveness of messenger RNA vaccines against infection with SARS-CoV-2 during the periods of Delta and Omicron variant predominance in Japan: the Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study Mimura, Wataru Ishiguro, Chieko Maeda, Megumi Murata, Fumiko Fukuda, Haruhisa Int J Infect Dis Short Communication OBJECTIVES: We aimed to evaluate COVID-19 messenger RNA vaccine effectiveness during the Delta- and Omicron-predominant periods in Japan. METHODS: We conducted a population-based cohort study among individuals aged 16–64 years during two periods: the Delta-predominant period (July 1–December 31, 2021) and the Omicron-predominant period (January 1–March 29, 2022). RESULTS: When comparing individuals who were vaccinated with those who were unvaccinated, the effectiveness of a second dose against symptomatic infection was 89.8% (95% confidence interval [CI]: 80.5–94.7%) during the Delta-predominant period and 21.2% (95% CI: 11.0–30.3%) during the Omicron-predominant period. The effectiveness of a third dose against symptomatic infection was 71.8% (95% CI: 60.1–80.1%) during the Omicron-predominant period. CONCLUSION: Vaccine effectiveness against symptomatic infection decreased during the Omicron-predominant period but was maintained by a third dose. The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2022-12 2022-10-08 /pmc/articles/PMC9547653/ /pubmed/36220547 http://dx.doi.org/10.1016/j.ijid.2022.10.001 Text en © 2022 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Short Communication
Mimura, Wataru
Ishiguro, Chieko
Maeda, Megumi
Murata, Fumiko
Fukuda, Haruhisa
Effectiveness of messenger RNA vaccines against infection with SARS-CoV-2 during the periods of Delta and Omicron variant predominance in Japan: the Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study
title Effectiveness of messenger RNA vaccines against infection with SARS-CoV-2 during the periods of Delta and Omicron variant predominance in Japan: the Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study
title_full Effectiveness of messenger RNA vaccines against infection with SARS-CoV-2 during the periods of Delta and Omicron variant predominance in Japan: the Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study
title_fullStr Effectiveness of messenger RNA vaccines against infection with SARS-CoV-2 during the periods of Delta and Omicron variant predominance in Japan: the Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study
title_full_unstemmed Effectiveness of messenger RNA vaccines against infection with SARS-CoV-2 during the periods of Delta and Omicron variant predominance in Japan: the Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study
title_short Effectiveness of messenger RNA vaccines against infection with SARS-CoV-2 during the periods of Delta and Omicron variant predominance in Japan: the Vaccine Effectiveness, Networking, and Universal Safety (VENUS) study
title_sort effectiveness of messenger rna vaccines against infection with sars-cov-2 during the periods of delta and omicron variant predominance in japan: the vaccine effectiveness, networking, and universal safety (venus) study
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547653/
https://www.ncbi.nlm.nih.gov/pubmed/36220547
http://dx.doi.org/10.1016/j.ijid.2022.10.001
work_keys_str_mv AT mimurawataru effectivenessofmessengerrnavaccinesagainstinfectionwithsarscov2duringtheperiodsofdeltaandomicronvariantpredominanceinjapanthevaccineeffectivenessnetworkinganduniversalsafetyvenusstudy
AT ishigurochieko effectivenessofmessengerrnavaccinesagainstinfectionwithsarscov2duringtheperiodsofdeltaandomicronvariantpredominanceinjapanthevaccineeffectivenessnetworkinganduniversalsafetyvenusstudy
AT maedamegumi effectivenessofmessengerrnavaccinesagainstinfectionwithsarscov2duringtheperiodsofdeltaandomicronvariantpredominanceinjapanthevaccineeffectivenessnetworkinganduniversalsafetyvenusstudy
AT muratafumiko effectivenessofmessengerrnavaccinesagainstinfectionwithsarscov2duringtheperiodsofdeltaandomicronvariantpredominanceinjapanthevaccineeffectivenessnetworkinganduniversalsafetyvenusstudy
AT fukudaharuhisa effectivenessofmessengerrnavaccinesagainstinfectionwithsarscov2duringtheperiodsofdeltaandomicronvariantpredominanceinjapanthevaccineeffectivenessnetworkinganduniversalsafetyvenusstudy

Ejemplares similares